

INFORME DE BÚSQUEDA DE PATENTES				
N° de solicitud: NC2016/0004271				
CRITERIOS PARA LA BÚSQUEDA (Anexar pantallazo o reporte en PDF, junto con los boléanos utilizados*. Para el caso de secuencias, anexar alineamientos)				
Palabras clave utilizadas		ang2 OR ANGPT2 OR "Angiopoietin 2" antibody		
CLASIFICACIONES UTILIZADAS PARA LA BÚSQUEDA		CIP:		
DOCUMENTOS CONSIDERADOS RELEVANTES (documentos patentes, literatura no patente, etc...)				
Informes/Base de datos	N° de solicitud/ Autor**	Fecha de Publicación/Presentación (DD/MM/AAAA)	Reiv. afectadas (Con indicación, si procede, de las partes relevantes o números de secuencias)	Categorías especiales de los documentos citados***
SIPI (Obligatoria)	NA			
EPO	WO2011014469	03/02/2011	NA	A
	BROWN ET AL.	01/01/2010	NA	A
ISA(US)	US2011/0027286	03/02/2011	NA	A
	US2010/0159587	24/06/2010	NA	A
	US2006/0246071	02/11/2006	NA	A
	DALY ET AL. 2012	13/11/2012	NA	A
NCBI (seq id No. 1,3)	US7973140	19/12/2005	NA	A
Lens (seq id No. 1,3)	NA			
*** Categorías especiales de documentos citados:				
“A” documento que define el estado general de la técnica no considerado como particularmente relevante. “E” solicitud de patente o patente anterior pero publicada en la fecha de presentación internacional o en fecha posterior. “P” documento publicado antes de la fecha de presentación internacional pero con posterioridad a la fecha de prioridad reivindicada.		“X” documento particularmente relevante; la invención reivindicada no puede considerarse nueva o que implique una actividad inventiva por referencia al documento aisladamente considerado. “Y” documento particularmente relevante; la invención reivindicada no puede considerarse que implique una actividad inventiva cuando el documento se asocia a otro u otros documentos de la misma naturaleza, cuya combinación resulta evidente para un experto en la materia.		
**** Indicar entre paréntesis la Autoridad que realizó la búsqueda o el informe preliminar Ejs: EPO, JP, INAPI.				

Literatura no patente **Se incluye entre otros, toda la referencia de la literatura no patente.	
---	--

Fecha del reporte de búsqueda:	29/01/2018
--------------------------------	------------

Sipi

Expediente No.	Título	Titular	Clasificación IPC
13230710	MOLÉCULA DE UNIÓN BIESPECÍFICA QUE SE UNE A DLL4 Y ANG2	BOEHRINGER INGELHEIM INTERNATIONAL GMBH	C07K 16/18; C07K 16/22
13230713	MOLÉCULAS BIESPECÍFICAS QUE COMPRENDEN DOMINIOS VHH DE UNIÓN A VEGF Y ANG2	BOEHRINGER INGELHEIM INTERNATIONAL GMBH	C07K 16/22; C07K 16/26
14170731	FORMULACIÓN FARMACÉUTICA QUE COMPRENDE UN ANTICUERPO ANTI-ANG2, HISTIDINA, POLISORBATO Y SACAROSA	REGENERON PHARMACEUTICALS, INC.	C07K 16/22; A61K 39/395; A61K 47/06; A61K 47/26
16079694	TERAPIA COMBINADA CON UN ANTICUERPO ANTI-ANG2 Y UN AGONISTA DE CD40	F. HOFFMANN- LA ROCHE AG	A61K 39/00; C07K 16/28; C07K 16/22; A61K 39/395
NC2016/0004266	COMPUESTOS QUE COMPRENDEN ANTICUERPOS FUSIONADOS POR DOS ENLAZANTES A DOS DERIVADOS DE POLIPÉPTIDOS DE FRAGMENTOS VARIABLES DE CADENA ÚNICA QUE SE UNEN A VEGFR2 Y ANG2	ELI LILLY AND COMPANY	C07K 16/28; C07K 16/22; C07K 16/46; A61K 39/395; A61P 35/00
NC2016/0004271	ANTICUERPOS ANG2	ELI LILLY AND COMPANY	A61K 39/395

Ncbi

Database	Nr All non-redundant GenBank
SEQ ID:	1

	Description	Max score	Total score	Query cover	E value	Ident	Accession
☐	immunoglobulin heavy chain VRC01c-HuGL [Homo sapiens]	199	199	100%	7e-64	81%	AMT74503.1
☐	Chain H, Crystal Structure Of An Antigen-Binding Fragment From A Humanized Version Of The An	201	201	100%	2e-63	80%	1IT9_H
☐	immunoglobulin heavy chain VRC01c-HuGL [Homo sapiens]	196	196	100%	8e-63	81%	AMT74517.1
☐	immunoglobulin heavy chain variable region [Homo sapiens]	196	196	100%	8e-63	82%	AOY40319.1
☐	immunoglobulin heavy chain VRC01c-HuGL [Homo sapiens]	196	196	100%	1e-62	80%	AMT74516.1
☐	anti-HIV immunoglobulin variable heavy chain, partial [synthetic construct]	195	195	100%	1e-62	81%	AMB38727.1
☐	immunoglobulin heavy chain variable region [Papio anubis]	196	196	100%	2e-62	77%	AAL96410.1
☐	humanized anti-DREG-200 immunoglobulin heavy chain variable region [synthetic construct]	195	195	100%	2e-62	80%	AAF21956.1

Database	Nr All non-redundant GenBank
SEQ ID:	3

	Description	Max score	Total score	Query cover	E value	Ident	Accession
☐	anti-rabies virus immunoglobulin light chain variable region [Homo sapiens]	187	187	100%	9e-60	85%	AAY33461.1
☐	Chain L, Crystal Structure Of The Envelope Glycoprotein Ectodomain From Dengue Virus Serotype	190	190	100%	3e-59	84%	3UAJ_L
☐	Chain L, Crystal Structure Of The Anti-ErbB2 Fab2c4	189	189	100%	3e-59	90%	1L7I_L
☐	anti-rabies virus immunoglobulin light chain variable region [Homo sapiens]	185	185	100%	5e-59	84%	AAY33423.1
☐	Chain B, Structure of Pertuzumab Fab with light chain Clambda at 2.16A	188	188	100%	8e-59	90%	4LLU_B
☐	immunoglobulin light chain variable region [Homo sapiens]	185	185	100%	8e-59	85%	AMB38586.1
☐	Chain B, Structure Of Myostatin In Complex With Humanized Rk35 Antibody	187	187	100%	2e-58	89%	5F3H_B
☐	Chain B, Crystal structure of Pertuzumab Clambda Fab with variable domain redesign (VRD2) at 1.	187	187	100%	3e-58	89%	4LLW_B

Database	Protein sequences derived from the Patent division of GenBank
Entrez terms	ang2 OR ANGPT2 OR "Angiopoietin 2"
SEQ ID:	1

	Description	Max score	Total score	Query cover	E value	Ident	Accession
☐	Sequence 1 from patent US 9695241	249	249	100%	2e-89	100%	AUF05542.1
☐	Sequence 21 from patent US 9580499	246	246	100%	3e-88	99%	ATK72177.1
☐	Sequence 2 from patent US 9695241	255	255	100%	2e-87	100%	AUF05543.1
☐	Sequence 19 from patent US 9580499	247	247	100%	9e-87	99%	ATK72175.1
☐	Sequence 22 from patent US 9580499	236	236	100%	2e-84	94%	ATK72178.1
☐	Sequence 38 from patent US 9580499	251	377	100%	6e-83	99%	ATK72187.1
☐	Sequence 20 from patent US 9580499	237	237	100%	7e-83	94%	ATK72176.1
☐	Sequence 10 from patent US 9580499	250	379	100%	7e-83	99%	ATK72166.1
☐	Sequence 11 from patent US 9580499	250	378	100%	8e-83	99%	ATK72167.1
☐	Sequence 40 from patent US 9580499	250	377	100%	8e-83	99%	ATK72189.1
☐	Sequence 9 from patent US 9580499	250	376	100%	8e-83	99%	ATK72165.1
☐	Sequence 12 from patent US 9580499	240	369	100%	8e-79	94%	ATK72168.1
☐	Sequence 582 from patent US 7973140	190	190	100%	3e-66	80%	AEK15296.1
☐	Sequence 449 from patent US 7973140	189	189	100%	2e-65	80%	AEK15217.1
☐	Sequence 497 from patent US 7973140	188	188	100%	3e-65	80%	AEK15241.1

Sequence 619 from patent US 7973140

Sequence ID: [AEK15333.1](#) Length: 116 Number of Matches: 1

Range 1: 1 to 115 [GenPept](#) [Graphics](#)

▼ Next Match ▲ Previous Match

Score	Expect	Method	Identities	Positives	Gaps
173 bits(439)	2e-59	Compositional matrix adjust.	98/121(81%)	102/121(84%)	6/121(4%)
Query 1	QVQLVQSGAEVKKPGASVKVSCKASGYSFTDYNMVWVRQAPGQGLEWMGYIDPYNGGTGY 60				
Sbjct 1	QVQLVQSGAEVKKPGASVKVSCKASGY+FT Y + WVRQAPGQGLEWMG+I YNG T Y 60				
Query 61	NQKFEGRVMTTDTSTSTAYMELRSLRSDDTAVYYCARTDRDYDVWYFDVWGQGLTVTVS 120				
Sbjct 61	AQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARYSS-----FDYWGQGLTVTVS 114				
Query 121	S 121				
Sbjct 115	S 115				

Database	Protein sequences derived from the Patent division of GenBank
Entrez terms	ang2 OR ANGPT2 OR "Angiopoietin 2"
SEQ ID:	3

	Description	Max score	Total score	Query cover	E value	Ident	Accession
☐	Sequence 3 from patent US 9695241	218	218	100%	1e-77	100%	AUF05544.1
☐	Sequence 4 from patent US 9695241	222	222	100%	2e-77	100%	AUF05545.1
☐	Sequence 23 from patent US 9580499	216	216	100%	2e-76	99%	ATK72179.1
☐	Sequence 19 from patent US 9580499	216	216	100%	2e-74	99%	ATK72175.1
☐	Sequence 10 from patent US 9580499	217	217	100%	3e-70	99%	ATK72166.1
☐	Sequence 9 from patent US 9580499	217	217	100%	3e-70	99%	ATK72165.1
☐	Sequence 11 from patent US 9580499	217	217	100%	3e-70	99%	ATK72167.1
☐	Sequence 40 from patent US 9580499	216	216	100%	3e-70	99%	ATK72189.1
☐	Sequence 38 from patent US 9580499	216	216	100%	3e-70	99%	ATK72187.1
☐	Sequence 24 from patent US 9580499	190	190	100%	2e-66	85%	ATK72180.1
☐	Sequence 20 from patent US 9580499	190	190	100%	1e-64	85%	ATK72176.1
☐	Sequence 432 from patent US 8987420	182	182	100%	4e-63	85%	AKX43104.1
☐	Sequence 12 from patent US 9580499	191	191	100%	1e-60	85%	ATK72168.1
☐	Sequence 658 from patent US 7973140	181	181	100%	5e-63	84%	AEK15372.1

! Gen ID: 15372.1 from GenBank

Sequence 658 from patent US 7973140

Sequence ID: [AEK15372.1](#) Length: 108 Number of Matches: 1

Range 1: 1 to 107 [GenPept](#) [Graphics](#)

▼ Next Match ▲ Previous Match

Score	Expect	Method	Identities	Positives	Gaps
181 bits(460)	5e-63	Compositional matrix adjust.	90/107(84%)	97/107(90%)	0/107(0%)
Query 1	DIQMTQSPSSVSASVGDRVTITCKASQDVYIAVAWYQQKPGKAPKLLIYWASTRDTGVPS 60				
Sbjct 1	DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYAASSLQSGVPS 60				
Query 61	RFSGSGSGTDFTLTISSLQPEDFATYYCHQYSSYPPTFGGGTKVEIK 107				
Sbjct 61	RFSGSGSGTDFTLTISSLQPEDFATYYCQANSFPLTFGGGKVEIK 107				

Query ID	Description	Seq Length	Seq Type	Worksheet Name	
WO_2015_179166_1		121aa	peptide	WO_2015_179166_1	
Patent Number	Title	Publication Date	SEQ ID NO	Local % Id	
US_2010_0092455_A1	NOVEL ANTI-PROLIFERATION ANTIBODIES	15/04/10	19	85.1%	
US_2012_0156191_A1	ANTI-JAM-A ANTIBODIES	21/06/12	19	85.1%	
US_2013_0303734_A1	NOVEL HOMOGENEOUS HUMANIZED ANTIPROLIFERATION ANTIBODIES	14/11/13	12	85.1%	
US_8071730_B2	Anti-JAM-A antibodies	06/12/11	19	85.1%	
WO_2008_062063_A1	NOVEL ANTIPROLIFERATION ANTIBODIES	29/05/08	19	85.1%	
JP_2010509931_A		02/04/10	51	85.1%	
EP_2455403_A1	Homogeneous humanized antibodies against JAM-A that inhibit proliferation	23/05/12	12	85.1%	
WO_2012_069550_A1	NOVEL HOMOGENEOUS HUMANIZED ANTIPROLIFERATION ANTIBODIES	31/05/12	12	85.1%	
CA_2670039_A1	NOVEL ANTIPROLIFERATION ANTIBODIES	29/05/08	19	85.1%	
US_2010_0092455_A1	NOVEL ANTI-PROLIFERATION ANTIBODIES	15/04/10	102	85.1%	
US_2012_0156191_A1	ANTI-JAM-A ANTIBODIES	21/06/12	102	85.1%	
US_8071730_B2	Anti-JAM-A antibodies	06/12/11	102	85.1%	
WO_2013_148296_A1	ANTIBODIES TO BRADYKININ B1 RECEPTOR LIGANDS	03/10/13	24	83.5%	
CA_2868353_A1	ANTIBODIES TO BRADYKININ B1 RECEPTOR LIGANDS	03/10/13	24	83.5%	
US_2013_0303734_A1	NOVEL HOMOGENEOUS HUMANIZED ANTIPROLIFERATION ANTIBODIES	14/11/13	10	82.6%	
EP_2455403_A1	Homogeneous humanized antibodies against JAM-A that inhibit proliferation	23/05/12	10	82.6%	
WO_2012_069550_A1	NOVEL HOMOGENEOUS HUMANIZED ANTIPROLIFERATION ANTIBODIES	31/05/12	10	82.6%	
WO_2013_148296_A1	ANTIBODIES TO BRADYKININ B1 RECEPTOR LIGANDS	03/10/13	135	83.5%	
CA_2868353_A1	ANTIBODIES TO BRADYKININ B1 RECEPTOR LIGANDS	03/10/13	135	83.5%	
US_2010_0092455_A1	NOVEL ANTI-PROLIFERATION ANTIBODIES	15/04/10	100	83.5%	
US_2012_0156191_A1	ANTI-JAM-A ANTIBODIES	21/06/12	100	83.5%	
US_8071730_B2	Anti-JAM-A antibodies	06/12/11	100	83.5%	
US_2009_0234106_A1	ANTI-ACTIVIN A ANTIBODIES AND USES THEREOF	17/09/09	218	82.6%	
US_2013_0030159_A1	ANTI-ACTIVIN A ANTIBODIES AND USES THEREOF	31/01/13	218	82.6%	
US_8309082_B2	Anti-activin A antibodies and uses thereof	13/11/12	218	82.6%	
JP_2010502740_A		28/01/10	233	82.6%	
WO_2008_031061_A2	ANTI-ACTIVIN A ANTIBODIES AND USES THEREOF	13/03/08	218	82.6%	
JP_2013107899_A	ANTI-ACTIVIN A ANTIBODY AND USE THEREOF	06/06/13	233	82.6%	
CA_2661878_A1	ANTI-ACTIVIN A ANTIBODIES AND USES THEREOF	13/03/08	218	82.6%	
US_2010_0092455_A1	NOVEL ANTI-PROLIFERATION ANTIBODIES	15/04/10	101	81.8%	
US_2012_0156191_A1	ANTI-JAM-A ANTIBODIES	21/06/12	101	81.8%	
US_8071730_B2	Anti-JAM-A antibodies	06/12/11	101	81.8%	
US_2013_0344509_A1	ANTI-HUMAN TROP-2 ANTIBODY HAVING AN ANTITUMOR ACTIVITY IN VIVO	26/12/13	95	82.8%	
WO_2013_077458_A1	ANTI-HUMAN TROP-2 ANTIBODY EXHIBITING ANTITUMOR ACTIVITY IN VIVO	30/05/13	97	82.8%	
CA_2855699_A1	ANTI-HUMAN TROP-2 ANTIBODY HAVING AN ANTITUMOR ACTIVITY IN VIVO	30/05/13	95	82.8%	
US_2012_0231006_A1	ANTI-ORAI1 ANTIGEN BINDING PROTEINS AND USES THEREOF	13/09/12	250	82.6%	
JP_2013511279_A		04/04/13	263	82.6%	
WO_2011_063277_A1	ANTI-ORAI1 ANTIGEN BINDING PROTEINS AND USES THEREOF	26/05/11	250	82.6%	
CA_2781532_A1	ANTI-ORAI1 ANTIGEN BINDING PROTEINS AND USES THEREOF	26/05/11	250	82.6%	
WO_2013_126810_A1	ANTI SEZ6 ANTIBODIES AND METHODS OF USE	29/08/13	173	83.5%	
CA_2865415_A1	ANTI SEZ6 ANTIBODIES AND METHODS OF USE	29/08/13	173	83.5%	
WO_2013_032032_A1	ANTI-HUMAN XCR1 ANTIBODIES	07/03/13	64	81.8%	
CA_2846370_A1	ANTI-HUMAN XCR1 ANTIBODIES	07/03/13	64	81.8%	
US_2005_0142635_A1	Reshaped human antibody to human interleukin-6 receptor	30/06/05	128	81.8%	

US 7479543 B2	Reshaped human antibody to human interleukin-6 receptor	20/01/09	128	81.8%	
US 2013 0344509 A1	ANTI-HUMAN TROP-2 ANTIBODY HAVING AN ANTITUMOR ACTIVITY IN VIVO	26/12/13	81	82.8%	
WO 2013 077458 A1	ANTI-HUMAN TROP-2 ANTIBODY EXHIBITING ANTITUMOR ACTIVITY IN VIVO	30/05/13	88	82.8%	
CA 2855699 A1	ANTI-HUMAN TROP-2 ANTIBODY HAVING AN ANTITUMOR ACTIVITY IN VIVO	30/05/13	81	82.8%	
US 2014 0105914 A1	HUMANISED ANTI CTLA-4 ANTIBODIES	17/04/14	35	81.1%	
WO 2012 120125 A1	HUMANISED ANTI CTLA-4 ANTIBODIES	13/09/12	35	81.1%	
KR 20140033013 A	HUMANISED ANTI CTLA-4 ANTIBODIES	17/03/14	35	81.1%	
US 2005 0142635 A1	Reshaped human antibody to human interleukin-6 receptor	30/06/05	126	81.8%	
US 7479543 B2	Reshaped human antibody to human interleukin-6 receptor	20/01/09	126	81.8%	
US 2009 0028877 A1	Antibody Composition Specifically Binding to Ganglioside Gm	29/01/09	23	82.6%	
US 2010 0111947 A1	PHARMACEUTICAL COMPOSITION COMPRISING ANTIBODY COMPOSITION WHICH SPECIFICALLY BINDS TO GANGLIOSIDE GM2	06/05/10	10	82.6%	
US 2011 0236374 A1	GENETICALLY RECOMBINANT ANTIBODY COMPOSITION CAPABLE OF BINDING SPECIFICALLY TO GANGLIOSIDE GM2	29/09/11	85	82.6%	
WO 2005 035578 A1	ANTIBODY COMPOSITION SPECIFICALLY BINDING TO GANGLIOSIDE GM2	21/04/05	31	82.6%	
WO 2008 090960 A1	GENETICALLY RECOMBINANT ANTIBODY COMPOSITION CAPABLE OF BINDING SPECIFICALLY TO GANGLIOSIDE GM2	31/07/08	85	82.6%	
WO 2010 018846 A1	DRUG CONTAINING ANTIBODY COMPOSITION SPECIFICALLY BINDING TO GANGLIOSIDE GM2	18/02/10	10	82.6%	
CA 2548787 A1	ANTIBODY COMPOSITION SPECIFICALLY BINDING TO GANGLIOSIDE GM2	21/04/05	23	82.6%	
US 2011 0027268 A1	ANTI-MESOTHELIN ANTIBODIES AND USES THEREOF	03/02/11	218	80.2%	
JP 2011504372 A		10/02/11	304	80.2%	
WO 2009 068204 A1	ANTI-MESOTHELIN ANTIBODIES AND USES THEREFOR	04/06/09	218	80.2%	
US 2005 0142635 A1	Reshaped human antibody to human interleukin-6 receptor	30/06/05	129	81.1%	
US 7479543 B2	Reshaped human antibody to human interleukin-6 receptor	20/01/09	129	81.1%	
US 2013 0344509 A1	ANTI-HUMAN TROP-2 ANTIBODY HAVING AN ANTITUMOR ACTIVITY IN VIVO	26/12/13	94	82.1%	
WO 2013 077458 A1	ANTI-HUMAN TROP-2 ANTIBODY EXHIBITING ANTITUMOR ACTIVITY IN VIVO	30/05/13	96	82.1%	
CA 2855699 A1	ANTI-HUMAN TROP-2 ANTIBODY HAVING AN ANTITUMOR ACTIVITY IN VIVO	30/05/13	94	82.1%	
US 2005 0142635 A1	Reshaped human antibody to human interleukin-6 receptor	30/06/05	127	81.1%	
US 2005 0215565 A1	Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents	29/09/05	50	81.1%	
US 2005 0260193 A1	Steroid sparing agents and methods of using same	24/11/05	50	81.1%	
US 2006 0004019 A1	Steroid sparing agents and methods of using same	05/01/06	50	81.1%	
US 2006 0110394 A1	Humanized anti-VLA 4 immunoglobulins and uses thereof	25/05/06	41	81.1%	
US 2005 0069541 A1	Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents	31/03/05	50	81.1%	
US 2010 0081793 A1	THERAPEUTIC USES OF HUMANIZED ANTIBODIES AGAINST ALPHA-4 INTEGRIN	01/04/10	41	81.1%	
US 2013 0059337 A1	Therapeutic Uses of Humanized Antibodies Against ALPHA-4 Integrin	07/03/13	41	81.1%	
US 7435802 B2	Humanized anti-VLA4 immunoglobulins	14/10/08	41	81.1%	
US 7479543 B2	Reshaped human antibody to human interleukin-6 receptor	20/01/09	127	81.1%	
US 7576101 B2	Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents	18/08/09	50	81.1%	
US 8246958 B2	Methods of inhibiting alpha-4-dependent interactions with VCAM-1 with anti-VLA-4 antibodies	21/08/12	41	81.1%	
JP 2006516624 A		06/07/06	54	81.1%	
JP 2006045237 A	HOMINIZED ANTIBODY AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4	16/02/06	41	81.1%	
JP 2007531735 A		08/11/07	50	81.1%	
JP 2007531761 A		08/11/07	50	81.1%	
JP 2009029781 A	THERAPEUTIC USE OF HUMANIZED ANTIBODIES AGAINST ALPHA-4 INTEGRIN	12/02/09	41	81.1%	

EP 1759709 B1	Humanized antibodies against leukocyte adhesion molecule VLA-4	27/02/13	41	81.1%	
JP 2011225577 A	COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASE AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENT	10/11/11	54	81.1%	
JP 2013165718 A	HUMANIZED ANTIBODY AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4	29/08/13	41	81.1%	
JP 2013173738 A	HUMANIZED ANTIBODY AGAINST LEUKOCYTE ADHESION MOLECULE VLA-4	05/09/13	41	81.1%	
JP 2014040458 A	COMPOSITION FOR DEMYELINATION DISEASE AND PARALYSIS, AND TREATMENT THEREOF BY ADMINISTRATION OF REMYELINATION AGENT	06/03/14	54	81.1%	
JP 2013166765 A	STEROID SPARING AGENT AND METHOD FOR USING THE SAME	29/08/13	50	81.1%	
US 5840299 A	Humanized antibodies against leukocyte adhesion molecule VLA-4	24/11/98	41	81.1%	
CA 2561164 A1	STEROID SPARING AGENTS AND THEIR USE	20/10/05	50	81.1%	
CA 2237808 A1	THERAPEUTIC USES OF HUMANIZED ANTIBODIES AGAINST ALPHA-4 INTEGRIN	29/05/97	41	81.1%	
CA 2514117 A1	COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS	12/08/04	50	81.1%	
CA 2514125 A1	COMPOSITION FOR AND TREATMENT OF DEMYELINATING DISEASES AND PARALYSIS BY ADMINISTRATION OF REMYELINATING AGENTS	12/08/04	50	81.1%	
CA 2694418 A1	NOVEL ANTIBODIES INHIBITING C-MET DIMERIZATION, AND USES THEREOF	15/01/09	77	81.8%	
CA 2694418 A1	NOVEL ANTIBODIES INHIBITING C-MET DIMERIZATION, AND USES THEREOF	15/01/09	83	81.8%	
CA 2888691 A1	NOVEL ANTIBODIES INHIBITING C-MET DIMERIZATION, AND USES THEREOF	15/01/09	77	81.8%	
CA 2888691 A1	NOVEL ANTIBODIES INHIBITING C-MET DIMERIZATION, AND USES THEREOF	15/01/09	83	81.8%	
CA 2982484 A1	NOVEL ANTIBODIES INHIBITING C-MET DIMERIZATION, AND USES THEREOF	15/01/09	77	81.8%	
CA 2982484 A1	NOVEL ANTIBODIES INHIBITING C-MET DIMERIZATION, AND USES THEREOF	15/01/09	83	81.8%	
US 5800815 A	Antibodies to P-selectin and their uses	01/09/98	9	79.3%	
US 6033667 A	Method for detecting the presence of P-selectin	07/03/00	9	79.3%	
US 2014 0105914 A1	HUMANISED ANTI CTLA-4 ANTIBODIES	17/04/14	34	80.2%	
WO 2012 120125 A1	HUMANISED ANTI CTLA-4 ANTIBODIES	13/09/12	34	80.2%	
KR 20140033013 A	HUMANISED ANTI CTLA-4 ANTIBODIES	17/03/14	34	80.2%	
US 2010 0196390 A1	AGONIST ANTI-TRKB MONOCLONAL ANTIBODIES	05/08/10	101	78.9%	
WO 2010 086828 A2	AGONIST ANTI-TRKB MONOCLONAL ANTIBODIES	05/08/10	101	78.9%	
US 2010 0330089 A1	ANTI-CD20 THERAPEUTIC COMPOSITIONS AND METHODS	30/12/10	9	81.8%	
US 2012 0114646 A1	LYOPHILIZED FORMULATIONS FOR SMALL MODULAR IMMUNOPHARMACEUTICALS	10/05/12	9	81.8%	
US 2012 0141497 A1	METHODS OF PURIFYING SMALL MODULAR IMMUNOPHARMACEUTICAL PROTEINS	07/06/12	9	81.8%	
JP 2010209068 A	METHOD FOR PURIFYING SMALL MODULAR IMMUNOPHARMACEUTICAL PROTEIN	24/09/10	9	81.8%	
JP 2010531137 A		24/09/10	70	81.8%	
WO 2008 156713 A2	ANTI-CD20 THERAPEUTIC COMPOSITIONS AND METHODS	24/12/08	9	81.8%	
JP 2012530721 A		06/12/12	9	81.8%	
WO 2010 147686 A2	METHODS OF PURIFYING SMALL MODULAR IMMUNOPHARMACEUTICAL PROTEINS	23/12/10	9	81.8%	
CA 2691322 A1	ANTI-CD20 THERAPEUTIC COMPOSITIONS AND METHODS	24/12/08	9	81.8%	
CA 2764180 A1	LYOPHILIZED FORMULATIONS FOR SMALL MODULAR IMMUNOPHARMACEUTICALS	23/12/10	9	81.8%	
CA 2751000 A1	METHODS OF PURIFYING SMALL MODULAR IMMUNOPHARMACEUTICAL PROTEINS	23/12/10	9	81.8%	
US 2010 0330089 A1	ANTI-CD20 THERAPEUTIC COMPOSITIONS AND METHODS	30/12/10	26	81.8%	
US 2012 0114646 A1	LYOPHILIZED FORMULATIONS FOR SMALL MODULAR IMMUNOPHARMACEUTICALS	10/05/12	26	81.8%	

US 2012 0141497 A1	METHODS OF PURIFYING SMALL MODULAR IMMUNOPHARMACEUTICAL PROTEINS	07/06/12	26	81.8%	
JP 2010209068 A	METHOD FOR PURIFYING SMALL MODULAR IMMUNOPHARMACEUTICAL PROTEIN	24/09/10	26	81.8%	
JP 2010531137 A		24/09/10	87	81.8%	
WO 2008 156713 A2	ANTI-CD20 THERAPEUTIC COMPOSITIONS AND METHODS	24/12/08	26	81.8%	
JP 2012530721 A		06/12/12	26	81.8%	
WO 2010 147686 A2	METHODS OF PURIFYING SMALL MODULAR IMMUNOPHARMACEUTICAL PROTEINS	23/12/10	26	81.8%	
CA 2691322 A1	ANTI-CD20 THERAPEUTIC COMPOSITIONS AND METHODS	24/12/08	26	81.8%	
CA 2764180 A1	LYOPHILIZED FORMULATIONS FOR SMALL MODULAR IMMUNOPHARMACEUTICALS	23/12/10	26	81.8%	
CA 2751000 A1	METHODS OF PURIFYING SMALL MODULAR IMMUNOPHARMACEUTICAL PROTEINS	23/12/10	26	81.8%	
US 2010 0330089 A1	ANTI-CD20 THERAPEUTIC COMPOSITIONS AND METHODS	30/12/10	24	81.8%	
US 2012 0114646 A1	LYOPHILIZED FORMULATIONS FOR SMALL MODULAR IMMUNOPHARMACEUTICALS	10/05/12	24	81.8%	
US 2012 0141497 A1	METHODS OF PURIFYING SMALL MODULAR IMMUNOPHARMACEUTICAL PROTEINS	07/06/12	24	81.8%	
JP 2010209068 A	METHOD FOR PURIFYING SMALL MODULAR IMMUNOPHARMACEUTICAL PROTEIN	24/09/10	24	81.8%	
JP 2010531137 A		24/09/10	85	81.8%	
WO 2008 156713 A2	ANTI-CD20 THERAPEUTIC COMPOSITIONS AND METHODS	24/12/08	24	81.8%	
JP 2012530721 A		06/12/12	24	81.8%	
WO 2010 147686 A2	METHODS OF PURIFYING SMALL MODULAR IMMUNOPHARMACEUTICAL PROTEINS	23/12/10	24	81.8%	
CA 2691322 A1	ANTI-CD20 THERAPEUTIC COMPOSITIONS AND METHODS	24/12/08	24	81.8%	
CA 2764180 A1	LYOPHILIZED FORMULATIONS FOR SMALL MODULAR IMMUNOPHARMACEUTICALS	23/12/10	24	81.8%	
CA 2751000 A1	METHODS OF PURIFYING SMALL MODULAR IMMUNOPHARMACEUTICAL PROTEINS	23/12/10	24	81.8%	
US 2010 0330089 A1	ANTI-CD20 THERAPEUTIC COMPOSITIONS AND METHODS	30/12/10	22	81.8%	
US 2012 0114646 A1	LYOPHILIZED FORMULATIONS FOR SMALL MODULAR IMMUNOPHARMACEUTICALS	10/05/12	22	81.8%	
US 2012 0141497 A1	METHODS OF PURIFYING SMALL MODULAR IMMUNOPHARMACEUTICAL PROTEINS	07/06/12	22	81.8%	
JP 2010209068 A	METHOD FOR PURIFYING SMALL MODULAR IMMUNOPHARMACEUTICAL PROTEIN	24/09/10	22	81.8%	
JP 2010531137 A		24/09/10	83	81.8%	
WO 2008 156713 A2	ANTI-CD20 THERAPEUTIC COMPOSITIONS AND METHODS	24/12/08	22	81.8%	
JP 2012530721 A		06/12/12	22	81.8%	
WO 2010 147686 A2	METHODS OF PURIFYING SMALL MODULAR IMMUNOPHARMACEUTICAL PROTEINS	23/12/10	22	81.8%	
CA 2691322 A1	ANTI-CD20 THERAPEUTIC COMPOSITIONS AND METHODS	24/12/08	22	81.8%	
CA 2764180 A1	LYOPHILIZED FORMULATIONS FOR SMALL MODULAR IMMUNOPHARMACEUTICALS	23/12/10	22	81.8%	
CA 2751000 A1	METHODS OF PURIFYING SMALL MODULAR IMMUNOPHARMACEUTICAL PROTEINS	23/12/10	22	81.8%	
US 2010 0092455 A1	NOVEL ANTI-PROLIFERATION ANTIBODIES	15/04/10	92	78.5%	

US 2012 0156191 A1	ANTI-JAM-A ANTIBODIES	21/06/12	92	78.5%	
US 8071730 B2	Anti-JAM-A antibodies	06/12/11	92	78.5%	
US 2010 0330089 A1	ANTI-CD20 THERAPEUTIC COMPOSITIONS AND METHODS	30/12/10	25	81.8%	
US 2012 0114646 A1	LYOPHILIZED FORMULATIONS FOR SMALL MODULAR IMMUNOPHARMACEUTICALS	10/05/12	25	81.8%	
US 2012 0141497 A1	METHODS OF PURIFYING SMALL MODULAR IMMUNOPHARMACEUTICAL PROTEINS	07/06/12	25	81.8%	
JP 2010209068 A	METHOD FOR PURIFYING SMALL MODULAR IMMUNOPHARMACEUTICAL PROTEIN	24/09/10	25	81.8%	
JP 2010531137 A		24/09/10	86	81.8%	
WO 2008 156713 A2	ANTI-CD20 THERAPEUTIC COMPOSITIONS AND METHODS	24/12/08	25	81.8%	
JP 2012530721 A		06/12/12	25	81.8%	
WO 2010 147686 A2	METHODS OF PURIFYING SMALL MODULAR IMMUNOPHARMACEUTICAL PROTEINS	23/12/10	25	81.8%	
CA 2691322 A1	ANTI-CD20 THERAPEUTIC COMPOSITIONS AND METHODS	24/12/08	25	81.8%	
CA 2764180 A1	LYOPHILIZED FORMULATIONS FOR SMALL MODULAR IMMUNOPHARMACEUTICALS	23/12/10	25	81.8%	
CA 2751000 A1	METHODS OF PURIFYING SMALL MODULAR IMMUNOPHARMACEUTICAL PROTEINS	23/12/10	25	81.8%	
US 2010 0092455 A1	NOVEL ANTI-PROLIFERATION ANTIBODIES	15/04/10	18	79.3%	
US 2012 0156191 A1	ANTI-JAM-A ANTIBODIES	21/06/12	18	79.3%	
US 8071730 B2	Anti-JAM-A antibodies	06/12/11	18	79.3%	
WO 2008 062063 A1	NOVEL ANTIPROLIFERATION ANTIBODIES	29/05/08	18	79.3%	
JP 2010509931 A		02/04/10	50	79.3%	
CA 2670039 A1	NOVEL ANTIPROLIFERATION ANTIBODIES	29/05/08	18	79.3%	
US 2010 0330089 A1	ANTI-CD20 THERAPEUTIC COMPOSITIONS AND METHODS	30/12/10	30	81.8%	
US 2012 0114646 A1	LYOPHILIZED FORMULATIONS FOR SMALL MODULAR IMMUNOPHARMACEUTICALS	10/05/12	30	81.8%	
US 2012 0141497 A1	METHODS OF PURIFYING SMALL MODULAR IMMUNOPHARMACEUTICAL PROTEINS	07/06/12	30	81.8%	
JP 2010209068 A	METHOD FOR PURIFYING SMALL MODULAR IMMUNOPHARMACEUTICAL PROTEIN	24/09/10	30	81.8%	
JP 2010531137 A		24/09/10	91	81.8%	
WO 2008 156713 A2	ANTI-CD20 THERAPEUTIC COMPOSITIONS AND METHODS	24/12/08	30	81.8%	
JP 2012530721 A		06/12/12	30	81.8%	
WO 2010 147686 A2	METHODS OF PURIFYING SMALL MODULAR IMMUNOPHARMACEUTICAL PROTEINS	23/12/10	30	81.8%	
CA 2691322 A1	ANTI-CD20 THERAPEUTIC COMPOSITIONS AND METHODS	24/12/08	30	81.8%	
CA 2764180 A1	LYOPHILIZED FORMULATIONS FOR SMALL MODULAR IMMUNOPHARMACEUTICALS	23/12/10	30	81.8%	
CA 2751000 A1	METHODS OF PURIFYING SMALL MODULAR IMMUNOPHARMACEUTICAL PROTEINS	23/12/10	30	81.8%	
US 2010 0291106 A1	COMPOSITIONS AND METHODS FOR ANTIBODIES TARGETING COMPLEMENT PROTEIN C3B	18/11/10	175	81.1%	
JP 2012525829 A		25/10/12	183	81.1%	
WO 2010 136311 A2	COMPOSITIONS AND METHODS FOR ANTIBODIES TARGETING COMPLEMENT PROTEIN C3B	02/12/10	175	81.1%	
CA 2760757 A1	COMPOSITIONS AND METHODS FOR ANTIBODIES TARGETING COMPLEMENT PROTEIN C3B	02/12/10	175	81.1%	

US 2010 0330089 A1	ANTI-CD20 THERAPEUTIC COMPOSITIONS AND METHODS	30/12/10	7	81.8%	
US 2012 0114646 A1	LYOPHILIZED FORMULATIONS FOR SMALL MODULAR IMMUNOPHARMACEUTICALS	10/05/12	7	81.8%	
US 2012 0141497 A1	METHODS OF PURIFYING SMALL MODULAR IMMUNOPHARMACEUTICAL PROTEINS	07/06/12	7	81.8%	
JP 2010209068 A	METHOD FOR PURIFYING SMALL MODULAR IMMUNOPHARMACEUTICAL PROTEIN	24/09/10	7	81.8%	
JP 2010531137 A		24/09/10	68	81.8%	
WO 2008 156713 A2	ANTI-CD20 THERAPEUTIC COMPOSITIONS AND METHODS	24/12/08	7	81.8%	
JP 2012530721 A		06/12/12	7	81.8%	
WO 2010 147686 A2	METHODS OF PURIFYING SMALL MODULAR IMMUNOPHARMACEUTICAL PROTEINS	23/12/10	7	81.8%	
CA 2691322 A1	ANTI-CD20 THERAPEUTIC COMPOSITIONS AND METHODS	24/12/08	7	81.8%	
CA 2764180 A1	LYOPHILIZED FORMULATIONS FOR SMALL MODULAR IMMUNOPHARMACEUTICALS	23/12/10	7	81.8%	
CA 2751000 A1	METHODS OF PURIFYING SMALL MODULAR IMMUNOPHARMACEUTICAL PROTEINS	23/12/10	7	81.8%	
US 2010 0330089 A1	ANTI-CD20 THERAPEUTIC COMPOSITIONS AND METHODS	30/12/10	18	81.8%	
US 2012 0114646 A1	LYOPHILIZED FORMULATIONS FOR SMALL MODULAR IMMUNOPHARMACEUTICALS	10/05/12	18	81.8%	
US 2012 0141497 A1	METHODS OF PURIFYING SMALL MODULAR IMMUNOPHARMACEUTICAL PROTEINS	07/06/12	18	81.8%	
JP 2010209068 A	METHOD FOR PURIFYING SMALL MODULAR IMMUNOPHARMACEUTICAL PROTEIN	24/09/10	18	81.8%	
JP 2010531137 A		24/09/10	79	81.8%	
WO 2008 156713 A2	ANTI-CD20 THERAPEUTIC COMPOSITIONS AND METHODS	24/12/08	18	81.8%	
JP 2012530721 A		06/12/12	18	81.8%	
WO 2010 147686 A2	METHODS OF PURIFYING SMALL MODULAR IMMUNOPHARMACEUTICAL PROTEINS	23/12/10	18	81.8%	
CA 2691322 A1	ANTI-CD20 THERAPEUTIC COMPOSITIONS AND METHODS	24/12/08	18	81.8%	
CA 2764180 A1	LYOPHILIZED FORMULATIONS FOR SMALL MODULAR IMMUNOPHARMACEUTICALS	23/12/10	18	81.8%	
CA 2751000 A1	METHODS OF PURIFYING SMALL MODULAR IMMUNOPHARMACEUTICAL PROTEINS	23/12/10	18	81.8%	
US 2010 0330089 A1	ANTI-CD20 THERAPEUTIC COMPOSITIONS AND METHODS	30/12/10	29	81.8%	
US 2012 0114646 A1	LYOPHILIZED FORMULATIONS FOR SMALL MODULAR IMMUNOPHARMACEUTICALS	10/05/12	29	81.8%	
US 2012 0141497 A1	METHODS OF PURIFYING SMALL MODULAR IMMUNOPHARMACEUTICAL PROTEINS	07/06/12	29	81.8%	
JP 2010209068 A	METHOD FOR PURIFYING SMALL MODULAR IMMUNOPHARMACEUTICAL PROTEIN	24/09/10	29	81.8%	
JP 2010531137 A		24/09/10	90	81.8%	
WO 2008 156713 A2	ANTI-CD20 THERAPEUTIC COMPOSITIONS AND METHODS	24/12/08	29	81.8%	
JP 2012530721 A		06/12/12	29	81.8%	
WO 2010 147686 A2	METHODS OF PURIFYING SMALL MODULAR IMMUNOPHARMACEUTICAL PROTEINS	23/12/10	29	81.8%	
CA 2691322 A1	ANTI-CD20 THERAPEUTIC COMPOSITIONS AND METHODS	24/12/08	29	81.8%	
CA 2764180 A1	LYOPHILIZED FORMULATIONS FOR SMALL MODULAR IMMUNOPHARMACEUTICALS	23/12/10	29	81.8%	

CA 2751000 A1	METHODS OF PURIFYING SMALL MODULAR IMMUNOPHARMACEUTICAL PROTEINS	23/12/10	29	81.8%	
US 2010 0330089 A1	ANTI-CD20 THERAPEUTIC COMPOSITIONS AND METHODS	30/12/10	52	81.8%	
US 2012 0114646 A1	LYOPHILIZED FORMULATIONS FOR SMALL MODULAR IMMUNOPHARMACEUTICALS	10/05/12	52	81.8%	
US 2012 0141497 A1	METHODS OF PURIFYING SMALL MODULAR IMMUNOPHARMACEUTICAL PROTEINS	07/06/12	52	81.8%	
JP 2010209068 A	METHOD FOR PURIFYING SMALL MODULAR IMMUNOPHARMACEUTICAL PROTEIN	24/09/10	52	81.8%	
JP 2010531137 A		24/09/10	113	81.8%	
WO 2008 156713 A2	ANTI-CD20 THERAPEUTIC COMPOSITIONS AND METHODS	24/12/08	52	81.8%	
JP 2012530721 A		06/12/12	52	81.8%	
WO 2010 147686 A2	METHODS OF PURIFYING SMALL MODULAR IMMUNOPHARMACEUTICAL PROTEINS	23/12/10	52	81.8%	
CA 2691322 A1	ANTI-CD20 THERAPEUTIC COMPOSITIONS AND METHODS	24/12/08	52	81.8%	
CA 2764180 A1	LYOPHILIZED FORMULATIONS FOR SMALL MODULAR IMMUNOPHARMACEUTICALS	23/12/10	52	81.8%	
CA 2751000 A1	METHODS OF PURIFYING SMALL MODULAR IMMUNOPHARMACEUTICAL PROTEINS	23/12/10	52	81.8%	
US 2010 0330089 A1	ANTI-CD20 THERAPEUTIC COMPOSITIONS AND METHODS	30/12/10	23	81.8%	
US 2012 0114646 A1	LYOPHILIZED FORMULATIONS FOR SMALL MODULAR IMMUNOPHARMACEUTICALS	10/05/12	23	81.8%	
US 2012 0141497 A1	METHODS OF PURIFYING SMALL MODULAR IMMUNOPHARMACEUTICAL PROTEINS	07/06/12	23	81.8%	
JP 2010209068 A	METHOD FOR PURIFYING SMALL MODULAR IMMUNOPHARMACEUTICAL PROTEIN	24/09/10	23	81.8%	
JP 2010531137 A		24/09/10	84	81.8%	
WO 2008 156713 A2	ANTI-CD20 THERAPEUTIC COMPOSITIONS AND METHODS	24/12/08	23	81.8%	
JP 2012530721 A		06/12/12	23	81.8%	
WO 2010 147686 A2	METHODS OF PURIFYING SMALL MODULAR IMMUNOPHARMACEUTICAL PROTEINS	23/12/10	23	81.8%	
CA 2691322 A1	ANTI-CD20 THERAPEUTIC COMPOSITIONS AND METHODS	24/12/08	23	81.8%	
CA 2764180 A1	LYOPHILIZED FORMULATIONS FOR SMALL MODULAR IMMUNOPHARMACEUTICALS	23/12/10	23	81.8%	
CA 2751000 A1	METHODS OF PURIFYING SMALL MODULAR IMMUNOPHARMACEUTICAL PROTEINS	23/12/10	23	81.8%	
US 2010 0330089 A1	ANTI-CD20 THERAPEUTIC COMPOSITIONS AND METHODS	30/12/10	44	81.8%	
US 2012 0114646 A1	LYOPHILIZED FORMULATIONS FOR SMALL MODULAR IMMUNOPHARMACEUTICALS	10/05/12	44	81.8%	
US 2012 0141497 A1	METHODS OF PURIFYING SMALL MODULAR IMMUNOPHARMACEUTICAL PROTEINS	07/06/12	44	81.8%	
JP 2010209068 A	METHOD FOR PURIFYING SMALL MODULAR IMMUNOPHARMACEUTICAL PROTEIN	24/09/10	44	81.8%	
JP 2010531137 A		24/09/10	105	81.8%	
WO 2008 156713 A2	ANTI-CD20 THERAPEUTIC COMPOSITIONS AND METHODS	24/12/08	44	81.8%	
JP 2012530721 A		06/12/12	44	81.8%	
WO 2010 147686 A2	METHODS OF PURIFYING SMALL MODULAR IMMUNOPHARMACEUTICAL PROTEINS	23/12/10	44	81.8%	
CA 2691322 A1	ANTI-CD20 THERAPEUTIC COMPOSITIONS AND METHODS	24/12/08	44	81.8%	

CA_2764180_A1	LYOPHILIZED FORMULATIONS FOR SMALL MODULAR IMMUNOPHARMACEUTICALS	23/12/10	44	81.8%	
CA_2751000_A1	METHODS OF PURIFYING SMALL MODULAR IMMUNOPHARMACEUTICAL PROTEINS	23/12/10	44	81.8%	
US_2010_0330089_A1	ANTI-CD20 THERAPEUTIC COMPOSITIONS AND METHODS	30/12/10	11	81.8%	
US_2012_0114646_A1	LYOPHILIZED FORMULATIONS FOR SMALL MODULAR IMMUNOPHARMACEUTICALS	10/05/12	11	81.8%	
US_2012_0141497_A1	METHODS OF PURIFYING SMALL MODULAR IMMUNOPHARMACEUTICAL PROTEINS	07/06/12	11	81.8%	
JP_2010209068_A	METHOD FOR PURIFYING SMALL MODULAR IMMUNOPHARMACEUTICAL PROTEIN	24/09/10	11	81.8%	
JP_2010531137_A		24/09/10	72	81.8%	
WO_2008_156713_A2	ANTI-CD20 THERAPEUTIC COMPOSITIONS AND METHODS	24/12/08	11	81.8%	
JP_2012530721_A		06/12/12	11	81.8%	
WO_2010_147686_A2	METHODS OF PURIFYING SMALL MODULAR IMMUNOPHARMACEUTICAL PROTEINS	23/12/10	11	81.8%	
CA_2691322_A1	ANTI-CD20 THERAPEUTIC COMPOSITIONS AND METHODS	24/12/08	11	81.8%	
CA_2764180_A1	LYOPHILIZED FORMULATIONS FOR SMALL MODULAR IMMUNOPHARMACEUTICALS	23/12/10	11	81.8%	
CA_2751000_A1	METHODS OF PURIFYING SMALL MODULAR IMMUNOPHARMACEUTICAL PROTEINS	23/12/10	11	81.8%	
US_2010_0330089_A1	ANTI-CD20 THERAPEUTIC COMPOSITIONS AND METHODS	30/12/10	12	81.8%	
US_2012_0114646_A1	LYOPHILIZED FORMULATIONS FOR SMALL MODULAR IMMUNOPHARMACEUTICALS	10/05/12	12	81.8%	
US_2012_0141497_A1	METHODS OF PURIFYING SMALL MODULAR IMMUNOPHARMACEUTICAL PROTEINS	07/06/12	12	81.8%	
JP_2010209068_A	METHOD FOR PURIFYING SMALL MODULAR IMMUNOPHARMACEUTICAL PROTEIN	24/09/10	12	81.8%	
JP_2010531137_A		24/09/10	73	81.8%	
WO_2008_156713_A2	ANTI-CD20 THERAPEUTIC COMPOSITIONS AND METHODS	24/12/08	12	81.8%	
JP_2012530721_A		06/12/12	12	81.8%	
WO_2010_147686_A2	METHODS OF PURIFYING SMALL MODULAR IMMUNOPHARMACEUTICAL PROTEINS	23/12/10	12	81.8%	
CA_2691322_A1	ANTI-CD20 THERAPEUTIC COMPOSITIONS AND METHODS	24/12/08	12	81.8%	
CA_2764180_A1	LYOPHILIZED FORMULATIONS FOR SMALL MODULAR IMMUNOPHARMACEUTICALS	23/12/10	12	81.8%	
CA_2751000_A1	METHODS OF PURIFYING SMALL MODULAR IMMUNOPHARMACEUTICAL PROTEINS	23/12/10	12	81.8%	
US_2010_0330089_A1	ANTI-CD20 THERAPEUTIC COMPOSITIONS AND METHODS	30/12/10	51	81.8%	
US_2012_0114646_A1	LYOPHILIZED FORMULATIONS FOR SMALL MODULAR IMMUNOPHARMACEUTICALS	10/05/12	51	81.8%	
US_2012_0141497_A1	METHODS OF PURIFYING SMALL MODULAR IMMUNOPHARMACEUTICAL PROTEINS	07/06/12	51	81.8%	
JP_2010209068_A	METHOD FOR PURIFYING SMALL MODULAR IMMUNOPHARMACEUTICAL PROTEIN	24/09/10	51	81.8%	
JP_2010531137_A		24/09/10	112	81.8%	
WO_2008_156713_A2	ANTI-CD20 THERAPEUTIC COMPOSITIONS AND METHODS	24/12/08	51	81.8%	
JP_2012530721_A		06/12/12	51	81.8%	

WO 2010 147686 A2	METHODS OF PURIFYING SMALL MODULAR IMMUNOPHARMACEUTICAL PROTEINS	23/12/10	51	81.8%	
CA 2691322 A1	ANTI-CD20 THERAPEUTIC COMPOSITIONS AND METHODS	24/12/08	51	81.8%	
Query ID	Description	Seq Length	Seq Type		
WO_2015_179166_3		107aa	peptide		
Patent Number	Title	Publication Date	SEQ ID NO	Local % Id	
US 2014 0030268 A1	TREATMENT FOR BONE DISEASES	30/01/14	336	94.4%	
US 2014 0030268 A1	TREATMENT FOR BONE DISEASES	30/01/14	368	94.4%	
US 2014 0127192 A1	METHOD FOR TREATING OSTEOPOROSIS	08/05/14	336	94.4%	
US 2014 0127192 A1	METHOD FOR TREATING OSTEOPOROSIS	08/05/14	368	94.4%	
US 2007 0072797 A1	Epitopes	29/03/07	336	94.4%	
US 2007 0072797 A1	Epitopes	29/03/07	368	94.4%	
US 2007 0110747 A1	Binding agents	17/05/07	336	94.4%	
US 2007 0110747 A1	Binding agents	17/05/07	368	94.4%	
US 2009 0074763 A1	METHOD FOR INHIBITING BONE RESORPTION	19/03/09	336	94.4%	
US 2009 0074763 A1	METHOD FOR INHIBITING BONE RESORPTION	19/03/09	368	94.4%	
US 2009 0304713 A1	BINDING AGENTS	10/12/09	336	94.4%	
US 2009 0304713 A1	BINDING AGENTS	10/12/09	368	94.4%	
US 2011 0044978 A1	METHOD FOR TREATING BONE FRACTURE	24/02/11	336	94.4%	
US 2011 0044978 A1	METHOD FOR TREATING BONE FRACTURE	24/02/11	368	94.4%	
US 2011 0097342 A1	BINDING AGENTS	28/04/11	336	94.4%	
US 2011 0097342 A1	BINDING AGENTS	28/04/11	368	94.4%	
US 2011 0262433 A1	METHOD FOR INHIBITING BONE RESORPTION	27/10/11	336	94.4%	
US 2011 0262433 A1	METHOD FOR INHIBITING BONE RESORPTION	27/10/11	368	94.4%	
US 2011 0268730 A1	METHOD FOR INHIBITING BONE RESORPTION	03/11/11	336	94.4%	
US 2011 0268730 A1	METHOD FOR INHIBITING BONE RESORPTION	03/11/11	368	94.4%	
US 2011 0305702 A1	EPITOPES	15/12/11	336	94.4%	
US 2011 0305702 A1	EPITOPES	15/12/11	368	94.4%	
US 2013 0121997 A1	BINDING AGENTS	16/05/13	336	94.4%	
US 2013 0121997 A1	BINDING AGENTS	16/05/13	368	94.4%	
US 2013 0202620 A1	HIGH CONCENTRATION ANTIBODY FORMULATIONS	08/08/13	236	94.4%	
US 2013 0203965 A1	Binding Agents	08/08/13	336	94.4%	
US 2013 0203965 A1	Binding Agents	08/08/13	368	94.4%	
US 2013 0287764 A1	METHOD FOR INHIBITING BONE RESORPTION	31/10/13	336	94.4%	
US 2013 0287764 A1	METHOD FOR INHIBITING BONE RESORPTION	31/10/13	368	94.4%	
US 7592429 B2	Sclerostin-binding antibody	22/09/09	336	94.4%	
US 7592429 B2	Sclerostin-binding antibody	22/09/09	368	94.4%	
US 7872106 B2	Sclerostin-binding antibodies	18/01/11	336	94.4%	
US 7872106 B2	Sclerostin-binding antibodies	18/01/11	368	94.4%	
US 8003108 B2	Sclerostin epitopes	23/08/11	336	94.4%	
US 8003108 B2	Sclerostin epitopes	23/08/11	368	94.4%	
US 8017120 B2	Method for inhibiting bone resorption	13/09/11	336	94.4%	
US 8017120 B2	Method for inhibiting bone resorption	13/09/11	368	94.4%	
US 8329176 B2	Method for inhibiting bone resorption	11/12/12	336	94.4%	
US 8329176 B2	Method for inhibiting bone resorption	11/12/12	368	94.4%	
US 8383801 B2	Polynucleotide encoding a sclerostin-binding antibody	26/02/13	336	94.4%	
US 8383801 B2	Polynucleotide encoding a sclerostin-binding antibody	26/02/13	368	94.4%	
US 8440193 B2	Method for inhibiting bone resorption	14/05/13	336	94.4%	

US 8440193 B2	Method for inhibiting bone resorption	14/05/13	368	94.4%	
US 8637643 B2	Sclerostin binding antibody	28/01/14	336	94.4%	
US 8637643 B2	Sclerostin binding antibody	28/01/14	368	94.4%	
US 8715663 B2	Epitopes	06/05/14	336	94.4%	
US 8715663 B2	Epitopes	06/05/14	368	94.4%	
JP 2008539726 A		20/11/08	362	94.4%	
JP 2008539726 A		20/11/08	380	94.4%	
JP 2009500296 A		08/01/09	362	94.4%	
JP 2009500296 A		08/01/09	380	94.4%	
WO 2006 119107 A2	BINDING AGENTS	09/11/06	336	94.4%	
WO 2006 119107 A2	BINDING AGENTS	09/11/06	368	94.4%	
WO 2006 119062 A2	EPITOPES	09/11/06	336	94.4%	
WO 2006 119062 A2	EPITOPES	09/11/06	368	94.4%	
JP 2011506483 A		03/03/11	362	94.4%	
JP 2011506483 A		03/03/11	380	94.4%	
JP 2014012001 A	SCLEROSTIN BINDING AGENTS	23/01/14	362	94.4%	
JP 2014012001 A	SCLEROSTIN BINDING AGENTS	23/01/14	380	94.4%	
JP 2013527176 A		27/06/13	239	94.4%	
WO 2009 039175 A2	METHOD FOR INHIBITING BONE RESORPTION	26/03/09	336	94.4%	
WO 2009 039175 A2	METHOD FOR INHIBITING BONE RESORPTION	26/03/09	368	94.4%	
WO 2009 079471 A1	METHOD FOR TREATING BONE FRACTURE WITH ANTI-SCLEROSTIN ANTIBODIES	25/06/09	336	94.4%	
WO 2009 079471 A1	METHOD FOR TREATING BONE FRACTURE WITH ANTI-SCLEROSTIN ANTIBODIES	25/06/09	368	94.4%	
JP 2013249303 A	SCLEROSTIN BINDING AGENT	12/12/13	362	94.4%	
JP 2013249303 A	SCLEROSTIN BINDING AGENT	12/12/13	380	94.4%	
JP 2014061000 A	SCLEROSTIN BINDING ACTION SUBSTANCE	10/04/14	362	94.4%	
JP 2014061000 A	SCLEROSTIN BINDING ACTION SUBSTANCE	10/04/14	380	94.4%	
WO 2011 143307 A1	HIGH CONCENTRATION ANTIBODY FORMULATIONS	17/11/11	236	94.4%	
WO 2012 145417 A1	METHOD FOR TREATING OSTEOPOROSIS	26/10/12	336	94.4%	
WO 2012 145417 A1	METHOD FOR TREATING OSTEOPOROSIS	26/10/12	368	94.4%	
WO 2013 019954 A1	METHOD FOR TREATING BONE GAP DEFECTS	07/02/13	336	94.4%	
WO 2013 019954 A1	METHOD FOR TREATING BONE GAP DEFECTS	07/02/13	368	94.4%	
WO 2013 101451 A1	METHOD OF TREATING ALVELOR BONE LOSS THROUGH THE USE OF ANTI-SCLEROSTIN ANTIBODIES	04/07/13	336	94.4%	
WO 2013 101451 A1	METHOD OF TREATING ALVELOR BONE LOSS THROUGH THE USE OF ANTI-SCLEROSTIN ANTIBODIES	04/07/13	368	94.4%	
WO 2014 006100 A1	TREATMENT FOR BONE DISEASES	09/01/14	336	94.4%	
WO 2014 006100 A1	TREATMENT FOR BONE DISEASES	09/01/14	368	94.4%	
CA 2707400 A1	METHOD FOR TREATING BONE FRACTURE WITH ANTI-SCLEROSTIN ANTIBODIES	25/06/09	336	94.4%	
CA 2707400 A1	METHOD FOR TREATING BONE FRACTURE WITH ANTI-SCLEROSTIN ANTIBODIES	25/06/09	368	94.4%	
CA 2699905 A1	METHOD FOR INHIBITING BONE RESORPTION	26/03/09	336	94.4%	
CA 2699905 A1	METHOD FOR INHIBITING BONE RESORPTION	26/03/09	368	94.4%	
CA 2842432 A1	METHOD FOR TREATING BONE GAP DEFECTS	07/02/13	336	94.4%	
CA 2842432 A1	METHOD FOR TREATING BONE GAP DEFECTS	07/02/13	368	94.4%	
CA 2858974 A1	METHOD OF TREATING ALVELOR BONE LOSS THROUGH THE USE OF ANTI-SCLEROSTIN ANTIBODIES	04/07/13	336	94.4%	

CA 2858974 A1	METHOD OF TREATING ALVELOR BONE LOSS THROUGH THE USE OF ANTI-SCLEROSTIN ANTIBODIES	04/07/13	368	94.4%	
CA 2947080 A1	SCLEROSTIN BINDING AGENTS	09/11/06	336	94.4%	
CA 2947080 A1	SCLEROSTIN BINDING AGENTS	09/11/06	368	94.4%	
US 2014 0030268 A1	TREATMENT FOR BONE DISEASES	30/01/14	319	94.4%	
US 2014 0127192 A1	METHOD FOR TREATING OSTEOPOROSIS	08/05/14	319	94.4%	
US 2007 0072797 A1	Epitopes	29/03/07	319	94.4%	
US 2007 0110747 A1	Binding agents	17/05/07	319	94.4%	
US 2009 0074763 A1	METHOD FOR INHIBITING BONE RESORPTION	19/03/09	319	94.4%	
US 2009 0304713 A1	BINDING AGENTS	10/12/09	319	94.4%	
US 2011 0044978 A1	METHOD FOR TREATING BONE FRACTURE	24/02/11	319	94.4%	
US 2011 0097342 A1	BINDING AGENTS	28/04/11	319	94.4%	
US 2011 0262433 A1	METHOD FOR INHIBITING BONE RESORPTION	27/10/11	319	94.4%	
US 2011 0268730 A1	METHOD FOR INHIBITING BONE RESORPTION	03/11/11	319	94.4%	
US 2011 0305702 A1	EPITOPES	15/12/11	319	94.4%	
US 2013 0121997 A1	BINDING AGENTS	16/05/13	319	94.4%	
US 2013 0203965 A1	Binding Agents	08/08/13	319	94.4%	
US 2013 0287764 A1	METHOD FOR INHIBITING BONE RESORPTION	31/10/13	319	94.4%	
US 7592429 B2	Sclerostin-binding antibody	22/09/09	319	94.4%	
US 7872106 B2	Sclerostin-binding antibodies	18/01/11	319	94.4%	
US 8003108 B2	Sclerostin epitopes	23/08/11	319	94.4%	
US 8017120 B2	Method for inhibiting bone resorption	13/09/11	319	94.4%	
US 8329176 B2	Method for inhibiting bone resorption	11/12/12	319	94.4%	
US 8383801 B2	Polynucleotide encoding a sclerostin-binding antibody	26/02/13	319	94.4%	
US 8440193 B2	Method for inhibiting bone resorption	14/05/13	319	94.4%	
US 8637643 B2	Sclerostin binding antibody	28/01/14	319	94.4%	
US 8715663 B2	Epitopes	06/05/14	319	94.4%	
JP 2008539726 A		20/11/08	347	94.4%	
JP 2009500296 A		08/01/09	347	94.4%	
WO 2006 119107 A2	BINDING AGENTS	09/11/06	319	94.4%	
WO 2006 119062 A2	EPITOPES	09/11/06	319	94.4%	
JP 2011506483 A		03/03/11	347	94.4%	
JP 2014012001 A	SCLEROSTIN BINDING AGENTS	23/01/14	347	94.4%	
WO 2009 039175 A2	METHOD FOR INHIBITING BONE RESORPTION	26/03/09	319	94.4%	
WO 2009 079471 A1	METHOD FOR TREATING BONE FRACTURE WITH ANTI-SCLEROSTIN ANTIBODIES	25/06/09	319	94.4%	
JP 2013249303 A	SCLEROSTIN BINDING AGENT	12/12/13	347	94.4%	
JP 2014061000 A	SCLEROSTIN BINDING ACTION SUBSTANCE	10/04/14	347	94.4%	
KR 20130126752 A	SCLEROSTIN BINDING AGENTS	20/11/13	319	94.4%	
WO 2012 145417 A1	METHOD FOR TREATING OSTEOPOROSIS	26/10/12	319	94.4%	
WO 2013 019954 A1	METHOD FOR TREATING BONE GAP DEFECTS	07/02/13	319	94.4%	
WO 2013 101451 A1	METHOD OF TREATING ALVELOR BONE LOSS THROUGH THE USE OF ANTI-SCLEROSTIN ANTIBODIES	04/07/13	319	94.4%	
WO 2014 006100 A1	TREATMENT FOR BONE DISEASES	09/01/14	319	94.4%	
CA 2707400 A1	METHOD FOR TREATING BONE FRACTURE WITH ANTI-SCLEROSTIN ANTIBODIES	25/06/09	319	94.4%	
CA 2699905 A1	METHOD FOR INHIBITING BONE RESORPTION	26/03/09	319	94.4%	
CA 2842432 A1	METHOD FOR TREATING BONE GAP DEFECTS	07/02/13	319	94.4%	

CA 2858974 A1	METHOD OF TREATING ALVELOR BONE LOSS THROUGH THE USE OF ANTI-SCLEROSTIN ANTIBODIES	04/07/13	319	94.4%	
CA 2947080 A1	SCLEROSTIN BINDING AGENTS	09/11/06	319	94.4%	
US 2014 0030268 A1	TREATMENT FOR BONE DISEASES	30/01/14	414	93.5%	
US 2014 0127192 A1	METHOD FOR TREATING OSTEOPOROSIS	08/05/14	414	93.5%	
US 2009 0060924 A1	ANTI-SCLEROSTIN ANTIBODIES	05/03/09	18	93.5%	
US 2010 0221263 A1	Anti-Sclerostin Antibodies	02/09/10	18	93.5%	
US 2011 0250205 A1	ANTI-SCLEROSTIN ANTIBODIES	13/10/11	18	93.5%	
US 2014 0056912 A1	METHODS OF TREATING SQUAMOUS CELL CARCINOMA	27/02/14	45	93.5%	
US 7744874 B2	Anti-sclerostin antibodies	29/06/10	18	93.5%	
US 7988970 B2	Methods of treatment comprising administering an anti-sclerostin antibody	02/08/11	18	93.5%	
US 8257704 B2	Anti-sclerostin antibodies	04/09/12	18	93.5%	
JP 2010524846 A		22/07/10	19	93.5%	
WO 2008 115732 A2	ANTI-SCLEROSTIN ANTIBODIES	25/09/08	18	93.5%	
JP 2013151504 A	ANTI-SCLEROSTIN ANTIBODY	08/08/13	19	93.5%	
WO 2012 149246 A1	METHODS OF TREATING SQUAMOUS CELL CARCINOMA RELATED APPLICATIONS	01/11/12	45	93.5%	
EP 2664346 A1	Anti-sclerostin antibodies	20/11/13	18	93.5%	
WO 2012 145417 A1	METHOD FOR TREATING OSTEOPOROSIS	26/10/12	414	93.5%	
WO 2013 019954 A1	METHOD FOR TREATING BONE GAP DEFECTS	07/02/13	414	93.5%	
WO 2013 101451 A1	METHOD OF TREATING ALVELOR BONE LOSS THROUGH THE USE OF ANTI-SCLEROSTIN ANTIBODIES	04/07/13	414	93.5%	
WO 2014 006100 A1	TREATMENT FOR BONE DISEASES	09/01/14	414	93.5%	
CA 2682212 C	ANTI-SCLEROSTIN ANTIBODIES	06/05/14	18	93.5%	
CA 2842432 A1	METHOD FOR TREATING BONE GAP DEFECTS	07/02/13	414	93.5%	
CA 2858974 A1	METHOD OF TREATING ALVELOR BONE LOSS THROUGH THE USE OF ANTI-SCLEROSTIN ANTIBODIES	04/07/13	414	93.5%	
US 2014 0030268 A1	TREATMENT FOR BONE DISEASES	30/01/14	402	93.5%	
US 2014 0127192 A1	METHOD FOR TREATING OSTEOPOROSIS	08/05/14	402	93.5%	
US 2009 0060924 A1	ANTI-SCLEROSTIN ANTIBODIES	05/03/09	6	93.5%	
US 2010 0221263 A1	Anti-Sclerostin Antibodies	02/09/10	6	93.5%	
US 2011 0250205 A1	ANTI-SCLEROSTIN ANTIBODIES	13/10/11	6	93.5%	
US 2014 0056912 A1	METHODS OF TREATING SQUAMOUS CELL CARCINOMA	27/02/14	43	93.5%	
US 7744874 B2	Anti-sclerostin antibodies	29/06/10	6	93.5%	
US 7988970 B2	Methods of treatment comprising administering an anti-sclerostin antibody	02/08/11	6	93.5%	
US 8257704 B2	Anti-sclerostin antibodies	04/09/12	6	93.5%	
JP 2010524846 A		22/07/10	13	93.5%	
WO 2008 115732 A2	ANTI-SCLEROSTIN ANTIBODIES	25/09/08	6	93.5%	
JP 2013151504 A	ANTI-SCLEROSTIN ANTIBODY	08/08/13	13	93.5%	
WO 2012 149246 A1	METHODS OF TREATING SQUAMOUS CELL CARCINOMA RELATED APPLICATIONS	01/11/12	43	93.5%	
EP 2664346 A1	Anti-sclerostin antibodies	20/11/13	6	93.5%	
WO 2012 145417 A1	METHOD FOR TREATING OSTEOPOROSIS	26/10/12	402	93.5%	
WO 2013 019954 A1	METHOD FOR TREATING BONE GAP DEFECTS	07/02/13	402	93.5%	
WO 2013 101451 A1	METHOD OF TREATING ALVELOR BONE LOSS THROUGH THE USE OF ANTI-SCLEROSTIN ANTIBODIES	04/07/13	402	93.5%	
WO 2014 006100 A1	TREATMENT FOR BONE DISEASES	09/01/14	402	93.5%	
CA 2682212 C	ANTI-SCLEROSTIN ANTIBODIES	06/05/14	6	93.5%	
CA 2842432 A1	METHOD FOR TREATING BONE GAP DEFECTS	07/02/13	402	93.5%	

CA 2858974 A1	METHOD OF TREATING ALVELOR BONE LOSS THROUGH THE USE OF ANTI-SCLEROSTIN ANTIBODIES	04/07/13	402	93.5%	
WO 2013 164689 A2	HUMANIZED PAN-HER ANTIBODY COMPOSITIONS	07/11/13	5	93.4%	
WO 2013 164689 A2	HUMANIZED PAN-HER ANTIBODY COMPOSITIONS	07/11/13	66	93.4%	
CA 2872226 A1	HUMANIZED PAN-HER ANTIBODY COMPOSITIONS	07/11/13	5	93.4%	
CA 2872226 A1	HUMANIZED PAN-HER ANTIBODY COMPOSITIONS	07/11/13	66	93.4%	
US 2007 0231333 A1	ANTI-5T4 ANTIBODIES AND USES THEREOF	04/10/07	84	92.5%	
US 2012 0064600 A1	ANTI-5T4 ANTIBODIES AND USES THEREOF	15/03/12	84	92.5%	
US 2012 0251558 A1	ANTIBODY-DRUG CONJUGATES	04/10/12	31	92.5%	
US 2013 0011418 A1	Antibody-Drug Conjugates	10/01/13	31	92.5%	
US 2014 0081005 A1	ANTIBODY-DRUG CONJUGATES	20/03/14	31	92.5%	
US 8044178 B2	Anti-5T4 antibodies and uses thereof	25/10/11	84	92.5%	
US 8309094 B2	Antibody-drug conjugates	13/11/12	31	92.5%	
US 8586049 B2	Antibody-drug conjugates	19/11/13	31	92.5%	
JP 2009529578 A		20/08/09	84	92.5%	
WO 2007 106744 A2	ANTI-5T4 ANTIBODIES AND USES THEREOF	20/09/07	84	92.5%	
WO 2012 131527 A1	ANTIBODY-DRUG CONJUGATES	04/10/12	31	92.5%	
CA 2645097 A1	ANTI-5T4 ANTIBODIES AND USES THEREOF	20/09/07	84	92.5%	
WO 2009 154283 A1	ANTIBODY DIRECTED AGAINST CALCIFIED GLOBULE, AND USE THEREOF	23/12/09	105	91.6%	
JP 2011042581 A	ANTIBODY AGAINST OXIDIZED LDL/beta2GPI COMPLEX AND USE THEREOF	03/03/11	53	91.6%	
WO 2013 164689 A2	HUMANIZED PAN-HER ANTIBODY COMPOSITIONS	07/11/13	45	91.5%	
WO 2013 164689 A2	HUMANIZED PAN-HER ANTIBODY COMPOSITIONS	07/11/13	47	91.5%	
CA 2872226 A1	HUMANIZED PAN-HER ANTIBODY COMPOSITIONS	07/11/13	45	91.5%	
CA 2872226 A1	HUMANIZED PAN-HER ANTIBODY COMPOSITIONS	07/11/13	47	91.5%	
US 2004 0096392 A1	Antibodies against cancer antigen TMEFF2 and uses thereof	20/05/04	34	91.6%	
US 2008 0044840 A1	ANTIBODIES AGAINST CANCER ANTIGEN TMEFF2 AND USES THEREOF	21/02/08	34	91.6%	
US 2008 0175846 A1	ANTIBODIES AGAINST CANCER ANTIGEN TMEFF2 AND USES THEREOF	24/07/08	34	91.6%	
US 2008 0160012 A1	ANTIBODIES AGAINST CANCER ANTIGEN TMEFF2 AND USES THEREOF	03/07/08	34	91.6%	
US 2011 0038864 A1	Antibodies Against Cancer Antigen TMEFF2 and Uses Thereof	17/02/11	34	91.6%	
US 7288248 B2	Antibodies against cancer antigen TMEFF2 and uses thereof	30/10/07	34	91.6%	
US 7674883 B2	Antibodies against cancer antigen TMEFF2 and uses thereof	09/03/10	34	91.6%	
US 7785816 B2	Antibodies against cancer antigen TMEFF2 and uses thereof	31/08/10	34	91.6%	
US 7824678 B2	Antibodies against cancer antigen TMEFF2 and uses thereof	02/11/10	34	91.6%	
US 8257708 B2	Antibodies against cancer antigen TMEFF2 and uses thereof	04/09/12	34	91.6%	
JP 2006502092 A		19/01/06	34	91.6%	
JP 2011121950 A	ANTIBODY AGAINST CANCER ANTIGEN TMEFF2 AND USE THEREOF	23/06/11	34	91.6%	
KR 101104655 B1	ANTIBODIES AGAINST CANCER ANTIGEN TMEFF2 AND USES THEREOF	13/01/12	34	91.6%	
WO 2009 154283 A1	ANTIBODY DIRECTED AGAINST CALCIFIED GLOBULE, AND USE THEREOF	23/12/09	106	91.6%	
JP 2011042581 A	ANTIBODY AGAINST OXIDIZED LDL/beta2GPI COMPLEX AND USE THEREOF	03/03/11	54	91.6%	
US 2012 0251558 A1	ANTIBODY-DRUG CONJUGATES	04/10/12	30	92.5%	
US 2013 0011418 A1	Antibody-Drug Conjugates	10/01/13	30	92.5%	
US 2014 0081005 A1	ANTIBODY-DRUG CONJUGATES	20/03/14	30	92.5%	
US 8309094 B2	Antibody-drug conjugates	13/11/12	30	92.5%	
US 8586049 B2	Antibody-drug conjugates	19/11/13	30	92.5%	
WO 2012 131527 A1	ANTIBODY-DRUG CONJUGATES	04/10/12	30	92.5%	